๐Ÿค– AI Analysis This analysis was generated by Claude (Anthropic) using the Free Energy Principle (Friston) and Monoamine Systems frameworks (Robbins), synthesising 35 peer-reviewed open-access papers from PubMed Central (2014โ€“2025). Not a substitute for medical advice.
2โ€“4%
of population affected
6:1
female-to-male ratio
8 years
average diagnosis delay
30.7%
of COVID survivors develop FM criteria
25.6%
pain reduction at progesterone peak

What is Fibromyalgia?

Fibromyalgia (FM) is a chronic pain syndrome characterised by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction ('fibro fog'), and heightened sensitivity to touch, light, and sound. It is classified in ICD-11 (code MG30.01) as 'chronic primary widespread pain' and as 'nociplastic pain' by the International Association for the Study of Pain (IASP, 2017).

โšก

Widespread Pain

Pain affecting all body quadrants, above and below the waist, for โ‰ฅ3 months

๐Ÿ˜ด

Non-Restorative Sleep

Alpha-delta sleep intrusion: waking brainwaves disrupt deep sleep, causing fatigue despite adequate sleep duration

๐Ÿง 

Cognitive Dysfunction

'Fibro fog': memory lapses, word-finding difficulties, impaired concentration โ€” linked to prefrontal norepinephrine deficit

๐Ÿ˜ฐ

Fatigue

Profound, unrelenting exhaustion unrelated to activity level; dopamine depletion in reward circuits plays a central role

๐ŸŒก๏ธ

Central Sensitisation

The nervous system is 'volume turned up': allodynia (pain from light touch), hyperalgesia (exaggerated pain), reduced pain thresholds throughout the body

๐Ÿฆ 

Associated Symptoms

IBS, headache/migraine, restless legs, sensitivity to temperature, anxiety, depression โ€” all linked to dysregulated monoamine systems

Diagnostic Criteria (ACR 2016)

  • WPI โ‰ฅ7 + SSS โ‰ฅ5, or WPI 4โ€“6 + SSS โ‰ฅ9
  • Symptoms present โ‰ฅ3 months
  • Not better explained by another disorder

Prevalence

  • Global: 2โ€“4%
  • Europe: 2.9โ€“4.7%
  • Korea: 7.5%
  • China: 0.03โ€“0.12%
  • Peak onset: 30โ€“55 years

The Science: Two Frameworks

๐Ÿ”ฎ

Karl J. Friston

Free Energy Principle & Active Inference

The brain is a prediction machine. In fibromyalgia, the generative model has failed: the brain assigns excessive precision to pain predictions, creating a self-reinforcing cycle of amplified pain that cannot be corrected by sensory evidence.

  • Central sensitisation = elevated precision on pain signals
  • Descending inhibition failure
  • Sleep disruption = failed recalibration
  • Gut-brain axis breakdown
โš—๏ธ

Trevor W. Robbins

Monoamine Systems & Descending Pain Control

Three neurotransmitters form the chemical backbone of pain control. In FM, all three are depleted: producing pain, fog, and fatigue simultaneously.

Serotonin
Raphe nucleus โ†’ Dorsal horn
FM: โ†“ โ†’ Pain amplification
Norepinephrine
Locus coeruleus โ†’ Dorsal horn
FM: โ†“ โ†’ Fibro fog, pain
Dopamine
Basal ganglia โ†’ Reward
FM: โ†“ โ†’ Fatigue, anhedonia

Post-COVID / Long COVID and Fibromyalgia

30.7%

of COVID-19 survivors met ACR fibromyalgia criteria at 6 months post-infection (Ursini et al., 2021, N=616)

FibroCOVID: A New Clinical Entity

Italian researchers coined 'FibroCOVID' after finding nearly 1 in 3 COVID-19 survivors developed FM symptoms within 6 months. This post-COVID FM shows unexpected male predominance (43%), driven by COVID severity as the trigger.

Predictor Odds Ratio 95% CI
Male gender 9.95 6.02โ€“16.43
Obesity 82.82 32.19โ€“213.08
BMI correlation R=0.763 p<0.0001

Shared Mechanisms: Long COVID = Fibromyalgia?

Goldenberg (2025) and Clauw & Calabrese (2023) conclude that long COVID, after excluding organ disease, is best understood as a central sensitisation syndrome โ€” identical to fibromyalgia and ME/CFS in mechanisms, neuroimaging, and treatment response.

Feature Long COVID Fibromyalgia
Widespread painโœ“โœ“
Post-exertional malaiseโœ“โœ“
Brain fogโœ“โœ“
Sleep disruptionโœ“โœ“
Neuroinflammationโœ“โœ“
Central sensitisationโœ“โœ“
Normal standard workupโœ“โœ“
SNRIs/TCAs effectiveโœ“โœ“
Opioids ineffectiveโœ“โœ“

The Friston View: Collapsed Inference After COVID

Active COVID-19 floods the brain with conflicting interoceptive signals. Post-COVID, the brain learns a pathological prior โ€” "I am sick and in pain" โ€” that persists even after viral clearance. Central sensitisation = a prediction error the brain cannot resolve.

COVID Mechanisms โ†’ FM

  • CNS neuroinvasion via ACE2
  • Cytokine storm: IL-1, IL-6, TNF-ฮฑ
  • Mitochondrial dysfunction
  • Oxidative stress
  • Gut microbiome dysbiosis
  • HPA axis dysregulation
  • Fascial myofibroblast activation
  • Monoamine depletion (all three)

Key Statistics

  • 30.7% post-COVID FM prevalence
  • 40โ€“90% develop post-COVID syndrome
  • 78% with moderate-severe insomnia
  • 50% FM depressed vs 17% RA controls

Menopause and Fibromyalgia

25.6%

pain reduction when progesterone peaks โ€” lost entirely after menopause (Schertzinger et al., 2018)

The Hormonal Pain Connection

Three sex hormones directly modulate pain. All three decline at menopause, eroding natural pain protection. The perimenopause โ€” maximum hormonal fluctuation โ€” is the peak FM onset window.

Progesterone
Analgesic via GABA-A. 25.6% pain reduction at peak.
Lost at menopause โ†’ pain amplification
Testosterone
Suppresses TNF-ฮฑ, decreases TRPV1 pain signals.
Declines with age โ†’ neuroinflammation increases
Estrogen
Stable = protective. Fluctuating = pain-amplifying. Upregulates serotonin.
Decline + fluctuation = maximum FM risk

The Estrogen-Serotonin-Pain Axis

Estrogen upregulates serotonin. At menopause: estrogen โ†“ โ†’ serotonin โ†“ โ†’ descending pain inhibition fails. Earlier menopause = shorter estrogen exposure = worse FM pain.

Friston: Menopause as Generative Model Disruption

At perimenopause, the brain cannot predict its own physiological state. Hot flashes = failed thermoregulatory inference. FM onset = the body's generative model breaking down under hormonal unpredictability.

Hormone Therapy Evidence

Study Intervention FM Outcome
Dias et al. 2023 (N=32) 12-week transdermal estradiol + oral progesterone 30% FIQ-R decline (p=0.0001)
Athnaiel et al. 2023 Steady HRT (review) 50% pain reduction

Key Insight: Stability > Level

It is not high estrogen that protects โ€” it is stable estrogen. Transdermal HRT outperforms oral preparations precisely because it avoids peak-trough fluctuations that amplify pain.

Prevalence at Menopause

  • FM peaks at 30โ€“55 years
  • 29% with climacteric symptoms have FM
  • vs. 4% without symptoms
  • FM: 7.9% โ†’ 10.4% postmenopausally

GPER: A Hidden Receptor

FM patients have elevated GPER despite normal estrogen โ€” receptor-level dysfunction, not just hormone deficiency. (Koca et al. 2019)

Kynurenine Pathway

Estrogen withdrawal โ†’ tryptophan โ†’ kynurenine โ†’ quinolinic acid (NMDA agonist) โ†’ central sensitisation. One pathway, explains everything.

Treatment: What Works

Non-Pharmacological (First-Line)

Strong evidence

Aerobic Exercise

Cochrane: 13 RCTs, 839 patients. Benefits last 24โ€“208 weeks.

Strong evidence

Cognitive Behavioural Therapy (CBT)

Most evidence for psychological interventions. Reduces catastrophising.

Moderate evidence

Tai Chi / Yoga / Qi Gong

Meta-analysis: 657 patients, significant improvements.

Moderate evidence

Acupuncture + Massage

Network meta-analysis: 99.2% probability of reducing FIQ (best combination).

Pharmacological

FDA Approved

Duloxetine (SNRI)

Addresses serotonin + NE deficit. Also reduces COVID-19 incidence.

FDA Approved

Milnacipran (SNRI)

50โ€“100 mg twice daily. Stronger NE effect.

FDA Approved

Pregabalin (Gabapentinoid)

NNT 4โ€“14. Reduces central sensitisation. Also benefits post-COVID.

Strong evidence

Amitriptyline (TCA)

Most evidence of all FM drugs. 36.5% improvement. 10โ€“25 mg nightly.

For Menopause + FM

Clinical evidence

Hormone Replacement Therapy (HRT)

Transdermal estradiol + micronized progesterone. 30% FIQ-R reduction at 12 weeks.

What Doesn't Work

Contraindicated

Opioids (pure mu-agonists)

Worsen central sensitisation. Contraindicated in all FM guidelines.

No evidence

NSAIDs

No benefit for nociplastic pain.

Convergence: The Double Vulnerability

Post-COVID

  • Neuroinflammation
  • HPA dysregulation
  • Monoamine depletion
  • Gut dysbiosis
  • Sleep disruption

Four Pillars

1. Neuroinflammation
2. HPA Dysregulation
3. Monoamine Depletion
4. Sleep Disruption
โ†“
FIBROMYALGIA

Menopause

  • Estrogen withdrawal โ†’ serotonin โ†“
  • Progesterone loss โ†’ GABA โ†“
  • Inflammaging (IL-6, TNF-ฮฑ)
  • HPA dysregulation
  • Sleep disruption (VMS)

The Double Vulnerability: When Both Occur Together

A perimenopausal woman who contracts severe COVID-19 faces simultaneous hormonal destabilisation AND viral-induced central sensitisation โ€” both pathways converging on the same four FM pillars. This represents compounding risk demanding active multidisciplinary intervention.

Treatment Convergence

Treatment FM Long COVID Menopausal FM Mechanism
SNRIs (duloxetine, milnacipran)โœ“โœ“โœ“โœ“โœ“โœ“โœ“โœ“Restore serotonin + NE
TCAs (amitriptyline)โœ“โœ“โœ“โœ“โœ“โœ“โœ“Serotonin + sleep
Pregabalin/Gabapentinโœ“โœ“โœ“โœ“โœ“โœ“โœ“Reduce central sensitisation
CBTโœ“โœ“โœ“โœ“โœ“โœ“โœ“โœ“โœ“Reduce catastrophising
Graded aerobic exerciseโœ“โœ“โœ“โœ“ (paced)โœ“โœ“โœ“Restore monoamines
HRT (transdermal)โ€”โ€”โœ“โœ“โœ“Restore estrogen-serotonin, progesterone GABA
Sleep optimisationโœ“โœ“โœ“โœ“โœ“โœ“โœ“โœ“โœ“Interrupt pain-sleep cycle

Sources & References

All documents from peer-reviewed open-access literature (PubMed Central / NIH).

Post-COVID / Long COVID

Menopause & Hormones

Core Fibromyalgia Research (21 papers)